ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use

Data presented at the American Society of Clinical Oncology annual meeting seem likely to shake up the ovarian cancer market. ImmunoGen, Inc.’s Phase III confirmatory MIRASOL trial of its antibody-drug conjugate Elahere (mirvetuximab soravtansine-gynx) supports a shift in treatment paradigms for patients with ovarian cancer resistant to platinum chemotherapy. Meanwhile, Sutro Biopharma, Inc.’s luveltamab tazevibulin presents a potential option for patients with levels of folate receptor alpha (FRα) expression too low to make them eligible for treatment with Elahere.

The MIRASOL trial, presented 4 June at ASCO, showed a statistically significant improvement on the primary endpoint of progression-free survival (PFS) as well as an overall survival benefit